371 related articles for article (PubMed ID: 22919601)
1. Glycoconjugates play a key role in Campylobacter jejuni Infection: interactions between host and pathogen.
Day CJ; Semchenko EA; Korolik V
Front Cell Infect Microbiol; 2012; 2():9. PubMed ID: 22919601
[TBL] [Abstract][Full Text] [Related]
2. The immunobiology of Campylobacter jejuni: Innate immunity and autoimmune diseases.
Phongsisay V
Immunobiology; 2016 Apr; 221(4):535-43. PubMed ID: 26709064
[TBL] [Abstract][Full Text] [Related]
3. A novel link between Campylobacter jejuni bacteriophage defence, virulence and Guillain-Barré syndrome.
Louwen R; Horst-Kreft D; de Boer AG; van der Graaf L; de Knegt G; Hamersma M; Heikema AP; Timms AR; Jacobs BC; Wagenaar JA; Endtz HP; van der Oost J; Wells JM; Nieuwenhuis EE; van Vliet AH; Willemsen PT; van Baarlen P; van Belkum A
Eur J Clin Microbiol Infect Dis; 2013 Feb; 32(2):207-26. PubMed ID: 22945471
[TBL] [Abstract][Full Text] [Related]
4. Low-Dose Exposure to Ganglioside-Mimicking Bacteria Tolerizes Human Macrophages to Guillain-Barré Syndrome-Associated Antigens.
Patry RT; Essler L; Andresen S; Quinn FD; Szymanski CM
mBio; 2021 Feb; 13(1):e0385221. PubMed ID: 35100875
[TBL] [Abstract][Full Text] [Related]
5. Structural heterogeneity of terminal glycans in Campylobacter jejuni lipooligosaccharides.
Semchenko EA; Day CJ; Moutin M; Wilson JC; Tiralongo J; Korolik V
PLoS One; 2012; 7(7):e40920. PubMed ID: 22815868
[TBL] [Abstract][Full Text] [Related]
6.
Stein RA
ACS Infect Dis; 2022 Oct; 8(10):1981-1991. PubMed ID: 36137262
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the specific interaction between sialoadhesin and sialylated Campylobacter jejuni lipooligosaccharides.
Heikema AP; Bergman MP; Richards H; Crocker PR; Gilbert M; Samsom JN; van Wamel WJ; Endtz HP; van Belkum A
Infect Immun; 2010 Jul; 78(7):3237-46. PubMed ID: 20421384
[TBL] [Abstract][Full Text] [Related]
8. Transplanted human fecal microbiota enhanced Guillain Barré syndrome autoantibody responses after Campylobacter jejuni infection in C57BL/6 mice.
Brooks PT; Brakel KA; Bell JA; Bejcek CE; Gilpin T; Brudvig JM; Mansfield LS
Microbiome; 2017 Aug; 5(1):92. PubMed ID: 28789710
[TBL] [Abstract][Full Text] [Related]
9. Molecular mimicry in Campylobacter jejuni: role of the lipo-oligosaccharide core oligosaccharide in inducing anti-ganglioside antibodies.
Perera VN; Nachamkin I; Ung H; Patterson JH; McConville MJ; Coloe PJ; Fry BN
FEMS Immunol Med Microbiol; 2007 Jun; 50(1):27-36. PubMed ID: 17374131
[TBL] [Abstract][Full Text] [Related]
10. EptC of Campylobacter jejuni mediates phenotypes involved in host interactions and virulence.
Cullen TW; O'Brien JP; Hendrixson DR; Giles DK; Hobb RI; Thompson SA; Brodbelt JS; Trent MS
Infect Immun; 2013 Feb; 81(2):430-40. PubMed ID: 23184526
[TBL] [Abstract][Full Text] [Related]
11. Role of Campylobacter jejuni infection in the pathogenesis of Guillain-Barré syndrome: an update.
Nyati KK; Nyati R
Biomed Res Int; 2013; 2013():852195. PubMed ID: 24000328
[TBL] [Abstract][Full Text] [Related]
12. CapC, a Novel Autotransporter and Virulence Factor of Campylobacter jejuni.
Mehat JW; Park SF; van Vliet AHM; La Ragione RM
Appl Environ Microbiol; 2018 Aug; 84(16):. PubMed ID: 29915112
[No Abstract] [Full Text] [Related]
13. Campylobacter jejuni: targeting host cells, adhesion, invasion, and survival.
Kemper L; Hensel A
Appl Microbiol Biotechnol; 2023 May; 107(9):2725-2754. PubMed ID: 36941439
[TBL] [Abstract][Full Text] [Related]
14. Assessment of glycan interactions of clinical and avian isolates of Campylobacter jejuni.
Day CJ; Tram G; Hartley-Tassell LE; Tiralongo J; Korolik V
BMC Microbiol; 2013 Oct; 13():228. PubMed ID: 24119179
[TBL] [Abstract][Full Text] [Related]
15. Guillain-Barré syndrome-related Campylobacter jejuni in Bangladesh: ganglioside mimicry and cross-reactive antibodies.
Islam Z; Gilbert M; Mohammad QD; Klaij K; Li J; van Rijs W; Tio-Gillen AP; Talukder KA; Willison HJ; van Belkum A; Endtz HP; Jacobs BC
PLoS One; 2012; 7(8):e43976. PubMed ID: 22952833
[TBL] [Abstract][Full Text] [Related]
16. Antibodies to gangliosides and galactocerebroside in patients with Guillain-Barré syndrome with preceding Campylobacter jejuni and other identified infections.
Hao Q; Saida T; Kuroki S; Nishimura M; Nukina M; Obayashi H; Saida K
J Neuroimmunol; 1998 Jan; 81(1-2):116-26. PubMed ID: 9521613
[TBL] [Abstract][Full Text] [Related]
17. Recognition characteristics of monoclonal antibodies that are cross-reactive with gangliosides and lipooligosaccharide from Campylobacter jejuni strains associated with Guillain-Barré and Fisher syndromes.
Houliston RS; Yuki N; Hirama T; Khieu NH; Brisson JR; Gilbert M; Jarrell HC
Biochemistry; 2007 Jan; 46(1):36-44. PubMed ID: 17198373
[TBL] [Abstract][Full Text] [Related]
18. Selective biochemical labeling of Campylobacter jejuni cell-surface glycoconjugates.
Whitworth GE; Imperiali B
Glycobiology; 2015 Jul; 25(7):756-66. PubMed ID: 25761366
[TBL] [Abstract][Full Text] [Related]
19. Glycan:glycan interactions: High affinity biomolecular interactions that can mediate binding of pathogenic bacteria to host cells.
Day CJ; Tran EN; Semchenko EA; Tram G; Hartley-Tassell LE; Ng PS; King RM; Ulanovsky R; McAtamney S; Apicella MA; Tiralongo J; Morona R; Korolik V; Jennings MP
Proc Natl Acad Sci U S A; 2015 Dec; 112(52):E7266-75. PubMed ID: 26676578
[TBL] [Abstract][Full Text] [Related]
20. The spectrum of immune responses to Campylobacter jejuni and glycoconjugates in Guillain-Barré syndrome and in other neuroimmunological disorders.
Enders U; Karch H; Toyka KV; Michels M; Zielasek J; Pette M; Heesemann J; Hartung HP
Ann Neurol; 1993 Aug; 34(2):136-44. PubMed ID: 8338338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
